Medivation Inc (MDVN) is Trading Lower on Unusual Volume for January 11

Equities Staff | |

Medivation Inc (MDVN) experienced unusually high volume on Jan. 11, as the stock lost 11.68% to a closing price of $35.97. The stock saw 3.32 million shares trade hands over the course of the day

Medivation Inc (MDVN) is Trading Higher on Unusual Volume for December 21

Equities Staff | |

Medivation Inc (MDVN) experienced unusually high volume on Dec. 21, as the stock gained 0.3% to a closing price of $43.79. The stock saw 2.39 million shares trade hands over the course of the day

5 Biotch Stocks to Watch for a Winning Strategy

The Life Sciences Report | |

Maxim Group Equity Analyst Jason McCarthy has developed a biotechnology theme that leverages immunotherapy platforms serving both cancer and infectious disease indications. It's an elegant

Early Stage Therapeutic Stocks to Watch

The Life Sciences Report | |

CAR T-cell therapies show amazing potential in treating blood cancers, but there's a lot of work to do before the cells are ready for commercialization. Alan Leong, senior analyst with

How the Immunotherapy Revolution is Changing the Way Investors Look at Biotechs

The Life Sciences Report | |

An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend. Do you go with an unknown company where the upside could be

Do the Math: Ram Selvaraju on the Appeal of Biotechs in Orphan Diseases

The Life Sciences Report | |

To cast a spotlight on disruptive biotechnology stocks, Raghuram "Ram" Selvaraju of Aegis Capital Corp. taps his experience as a molecular biologist, preclinical investigator and

How Did High Flyers Turn into Soul Searchers? Maxim Analyst Jason Kolbert on the Highs and Lows of Biotech Valuations

The Life Sciences Report | |

After soaring more than 56% last year, the NASDAQ Biotechnology Index is down almost 15% in March. In this interview with The Life Sciences Report, Jason Kolbert of the Maxim Group points to

Medivation Plunges on Low Sales Guidance for Xtandi

Joel Anderson | |

Small-cap biotechnology firm Medivation (MDVN) saw shares plummet almost 14.5 percent on Feb 28 after a Q4 2013 earnings report featured softer guidance for sales of its lead therapy, Xtandi,

Biotech, Health Care ETFs Fall for Third Straight Day

Joel Anderson | |

Biotech stocks continued a rough week on Wednesday, with the iShares Nasdaq Biotechnology Fund ($IBB) down more than 2.5 percent in early trading, and off by almost 9 percent since Monday. This

Aegis Capital Is Changing the Way Investors Look at HealthCare Stocks

Equities Editors Desk | |

For the entire furor surrounding the upcoming implementation of “Obamacare” at the start of next year, few have been able to advance anything that resembles a comprehensive assessment

Blockchain in Healthcare - Discussion at the EU Parliament

From the recent Blockchain For Europe Summit in Brussels: Panel on Digital Health - How Blockchain technology can make health care systems more patient-centric and sustainable